Bruker Corporation (NASDAQ: BRKR) and Accuray (NASDAQ:ARAY) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Bruker Corporation and Accuray’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Bruker Corporation $1.66 billion 2.93 $275.00 million $1.00 30.61
Accuray $383.41 million 0.90 $640,996.00 ($0.35) -11.86

Bruker Corporation has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Bruker Corporation, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.4% of Bruker Corporation shares are held by institutional investors. Comparatively, 76.7% of Accuray shares are held by institutional investors. 35.2% of Bruker Corporation shares are held by insiders. Comparatively, 2.9% of Accuray shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Bruker Corporation has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.


This table compares Bruker Corporation and Accuray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bruker Corporation 9.65% 26.66% 10.47%
Accuray -7.71% -61.62% -7.12%

Analyst Ratings

This is a summary of current ratings and target prices for Bruker Corporation and Accuray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bruker Corporation 2 8 3 0 2.08
Accuray 0 3 2 0 2.40

Bruker Corporation currently has a consensus price target of $26.00, indicating a potential downside of 15.06%. Accuray has a consensus price target of $6.00, indicating a potential upside of 44.58%. Given Accuray’s stronger consensus rating and higher probable upside, analysts clearly believe Accuray is more favorable than Bruker Corporation.


Bruker Corporation pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Accuray does not pay a dividend. Bruker Corporation pays out 16.0% of its earnings in the form of a dividend.


Bruker Corporation beats Accuray on 10 of the 15 factors compared between the two stocks.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices. It also focuses on nanomechanical testing instruments.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.